A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
Withdrawn
- Conditions
- Overactive Bladder (OAB)
- Registration Number
- NCT01317810
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.
- Detailed Description
Subjects will complete a study specific survey questionnaire at Screening and the Month 1 through Month 6 visits. Subjects will be followed for 6 months.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Subject has overactive bladder as determined by their prescribing physician
- Subject is currently receiving pharmacotherapy for overactive bladder
- Subject is willing to comply with required protocol/study requirements
Exclusion Criteria
- Subject has a history of a clinically significant illness or medical condition prior to screening that would preclude participation in the study
- Male subjects with Lower Urinary Tract Symptoms (LUTS) or Bladder Outlet Obstruction (BOO)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reason for change in OAB medication/treatment regimen 6 months Change in overactive bladder (OAB) medication/ treatment regimen 6 months
- Secondary Outcome Measures
Name Time Method Persistence of use of any OAB medication as reported by the Physician 6 months Change in OAB medication including discontinuation of OAB medication as reported by the Physician 6 months Subject reported efficacy 6 months Measured by the Subject Survey Questionnaire